Novo Holdings co-leads $181.4 million Series D financing in Alentis Therapeutics to advance groundbreaking antibody-drug conjugates for solid tumours

Funding to support development of first-in-class CLDN1 targeted medicinesStrong syndicate of international life science investorsOne of the largest ADC-focused private fundraisings globally in 2024View original content:https://www.prnewswire.co.uk/news-releases/novo-holdings-co-leads-181-4-million-series-d-financing-in-alentis-therapeutics-to-advance-groundbreaking-antibody-drug-conjugates-adcs-for-solid-tumours-302301684.html

en | boerse | 67933649 |